THIS WEBSITE CONTAINS FORWARD LOOKING STATEMENTS
All statements in this website and attached documents, including videos, are not historical facts and are forward-looking statements which involve risks and uncertainties; actual results may differ from the forward-looking statements. Sentences or phrases which use such words as “projected”, “expect”, “believe”, “anticipates”, “hopeful”, “looking”, “market penetration”, “goal”, “target”, “hopeful”, “should”, “working to”, “working toward”, ” pro-forma”, “developing”, “develop”, “research, “investing” and others indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
These forward looking statements and projections should not be relied upon, but are provided only to show a theoretical outcome. Actual results may be materially different. We cannot and do not warrant the accuracy, completeness or timeliness of the information contained therein. The statements in this document are not historical facts and are forward-looking statements which involve risks and uncertainties; actual results may differ from the forward-looking statements. Sentences or phrases that use such words as “pro-forma”, “projection”, “anticipates”, “attempt”, “target”, “develop”, “working to”, “working toward” and others indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
We caution you that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.
For further information, please contact us at:
Disclosure regarding Emerging Growth Research and Joseph Noel’s report on Kraig Labs: The following disclosure statement is taken from Emerging Growth Research’s report:
No compensation, in any form, was provided to the author of this report or to Emerging Growth Research, LLC for its production.
Information, opinions, or recommendations contained in this research report are submitted solely for informational purposes. The information used in statements of fact made has been obtained from sources considered reliable, but we neither guarantee nor represent their completeness or accuracy. Such information and the opinions expressed are subject to change without notice. This research report is not intended as an offering or a solicitation of any offer to buy or sell the securities mentioned or discussed. The firm, its principles, or the assigned analyst may or may not own or trade shares, options, or warrants of this covered Company. Emerging Growth Research, LLC, has not received, and will not receive compensation for the production of this report and other related services from the Company. The firm produced a research report in mid-2008 and received compensation for its production. Additionally, the analyst responsible for the production of this report owns common stock in the subject Company. This report should be considered a paid promotional piece and the author may or may not liquidate shares. The views expressed in this Company research report accurately reflect the analyst’s personal views about any or all of the subject securities or issuers referred to in this Company report, and no part of the analyst’s or the firm’s compensation was, or will be directly or indirectly related to the specific recommendation or views expressed in this report. Opinions expressed herein reflect the opinion of Emerging Growth Research, LLC and are subject to change without notice. We claim no responsibility to update the information contained in this report. Investors should consider the suitability of any particular investment based on their ability to accept certain levels of risk, and should not rely solely on this report for information pertaining to the Company covered. The material in this document is intended for general circulation only and the recommendations contained herein do not take into account the specific objectives, financial situation, or particular needs of any particular person. An investor should consult his/her investment representative regarding the suitability of this investment and take into account any specific investment objectives, financial situation, or particular needs before he or she makes a commitment to purchase the shares of this or any other Company’s stock. No part of this document may be reproduced in any manner without written consent of the Emerging Growth Research, LLC.
On Third-Party Video Content linked on our Videos Page: Third-party video content linked on this page is not within Kraig Biocraft Laboratories’ control. In playing these videos, or attempting to follow links attached to these videos, you understand that they are hosted via a third-party site – for instance, the University of Notre Dame’s YouTube Channel – and Kraig Labs is not responsible for their content.
Disclosure regarding ongoing investor relation efforts
ANN ARBOR, Mich., – June 5, 2018 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers announces today that it is continuing its efforts to commercialize its spider silk based technologies. The Company has been proud to share information relating to the recent approvals for its Vietnamese subsidiary, Prodigy Textiles. The Company has been and will continue to be active in its investment relations program to ensure that our shareholders and the public are keep up to date with our accomplishments and plans for the immediate future.
At the request of OTC Markets Group, the Company has reviewed its investor relations (IR) program and the most recent publications to ensure that it is holding its IR program and all vendors to our strict guidelines and expectations. While the Company did not have editorial control over the recent publication by Stellar Media Group, LLC, the documents that we have reviewed, in our opinion, are truthful and factual. The publication by Stellar Media Group, LLC was paid for by ACN, LLC, who was engaged as part of the Company’s IR program, and was compensated as part of Company’s ongoing IR efforts. The Company reviewed the publication as soon as we were aware of it on May 25, 2018.
Our policy has been that our IR providers make full and complete disclosure of any compensation they receive and that all information is factual, or if an honestly held opinion, is stated as an opinion. We have always held ourselves and our vendors to these standards as is well known to our shareholders.
Kraig Labs has long standing and productive working relationships with Hansel Capital and Karolus Maximus Kapital going back 5 or more years. These two firms provide the Company with support for shareholder inquiries and investor relations services. The Company has hired and directed these two supporting firms to create and provide shareholders and the public with updates and news on the Company’s progress. As a reporting Company, with fully audited financial statements, compensation in the form of stock to Karolus Maximus Kapital and Hansel Capital for their IR services has been fully disclosed and reported in the Company’s SEC filings going back to 2011. The Company issued approximately 30,000,000 shares of stock in 2017 for IR services and there has been no issuance of stock to date in 2018 for IR services. These public filings can be found on the Company’s website or through the SEC EDGAR system. In addition, we require all IR vendors or subcontractors to disclose their compensation in every IR document that is viewed by the public or our shareholders.
Based upon the documents we have reviewed, both of these firms remain in compliance with our strict policies and the documents contained only factual statements about the Company or clearly stated and honestly held opinions. The Company appreciates the great work our IR support team has done. We are very much aware of the added burden our strict compliance policies place on them and we thank them for their work and efforts. As a publicly traded company with audited and publicized financials we are, and our vendors are, open to public criticism in everything that we do. Knowing that we are under a microscope, we have always endeavored to set a standard in transparency. All purchases or sales of Company securities by officers, directors, or control persons in the last 90 days have been done through a 10B5-1 trading plan and were properly disclosed.
We believe that our independent IR team has done an excellent job of helping to share the exciting progress the Company is making. Our shareholders can expect to see us continue to work diligently to improve our fundamentals and to share the Company’s progress through all available and appropriate channels. Our recent announcement of our business licenses for our subsidiary in Vietnam are a major milestone for the Company and represent a strong shift to scaled production that we have been working diligently towards. The Company believes that the improvements in our fundamentals and spreading of the word of these positive changes, including the approvals from Vietnam and the creation of our subsidiary; through our website, press release, and investor relations providers have had a significant positive impact on our market dynamics. This is an exciting time for Kraig Labs and we believe there is a bright future for the Company and recombinant spider silk.
Disclosure regarding Optimo Holdings and investor relations
In November 2019 Optimo entered into an agreement with Kraig Biocraft Laboratories to provide consulting services including; investor relations, media purchasing and news coverage and website traffic to our investor portal. Optimo will receive twenty five thousand dollars a month for costs associated with the internet media purchases. Optimo has been compensated previously and currently does not own any shares of Kraig Biocraft Laboratories.
Disclosure concerning Hansel Capital, LLC
Kraig Biocraft Laboratories has contracted with Hansel Capital, LLC to provide ongoing investor and media relations services.